OCOren Cooper

Oren Cooper

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Oren Cooper has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Silane Self-Assembled Monolayers for High-Sensitivity, Ultra-Thin Surface Plasmon Resonance Biosensing

    by Oren Cooper, Christopher J. Day, Joe Tiralongo

    Recent advances in surface plasmon resonance (SPR) technology have enabled real-time, label-free detection of biomolecular interactions with exceptional sensitivity. However, the most common immobilization strategy using carboxymethyl dextran hydrogel matrices, can introduce steric hindrance, non-specific interactions, and decreased signal sensitivity due to their substantial thickness. The development of thinner, more uniform, and chemically versatile coatings remains essential for improving the performance of SPR-based biosensors. Herein, we investigate the use of chemical vapor deposition (CVD) of 3-(glycidyloxypropyl)trimethoxysilane (GOPTS) and 3-(triethoxysilyl)propyl isocyanate (TEPI) to generate self-assembled monolayers (SAMs) for covalent biofunctionalization of gold SPR sensor surfaces. Silane SAMs provide closer proximity of biomolecular binding sites to the plasmonic surface, enhancing assay sensitivity while eliminating the need for additional coupling agents through their inherent epoxide or isocynate reactivity. Using β2-microglobulin as a model analyte, we demonstrate that silane SAMs-modified SPR chips exhibit superior analyte sensitivity and stability compared to commercial SPR chips. These findings establish silane SAMs deposited via CVD as a robust, cost-effective, and reproducible biofunctionalization strategy for SPR systems, offering a framework that can be extended to other label-free detection platforms. More broadly, this approach provides a pathway toward next generation miniaturized and high-resolution biosensing technologies.

  • Open Access

    Characterization of a conserved outer-membrane protein in non-typeable Haemophilus influenzae with an unidentified impact on phenotype

    by Ashley J. Fraser, Oren Cooper, Brian M. Forde, Timothy F. Murphy, Michael P. Jennings, John M. Atack

    Non-typeable Haemophilus influenzae (NTHi) is an opportunistic bacterial pathogen of the human airway and is a cause of significant morbidity and mortality worldwide. No vaccine currently exists in part due to the incredible diversity and extreme variability exhibited both genetically and phenotypically between NTHi strains. For a vaccine to be successful, selection of appropriate antigens is key. Antigens need to show high conservation between strains, be present in most/all strains, and be stably expressed. The uncharacterized protein NTHI1101, initially identified from sequential isolates of NTHi from the sputum of COPD patients, demonstrated attributes of interest as a potential vaccine antigen: analysis of over 4,500 individual NTHi genomes demonstrated this protein was present in over 99% of strains, with over 80% amino acid identity. Further analysis predicted that NTHI1101 contained a lipoprotein signal sequence, meaning it was likely located in the outer membrane. An experimental determination of the location of the NTHI1101 protein demonstrated that although this protein was present in enriched outer-membrane fractions of NTHi cells, analysis with whole-cell enzyme-linked immunosorbent assays indicated it was not surface located. A variety of in vitro analyses with relevance to pathobiology demonstrated that the loss of the NTHI1101 protein had no impact on the phenotype of NTHi. Therefore, although this protein is highly conserved and almost universally present in NTHi, we conclude that the use of this protein as a target for novel therapeutics is perhaps not warranted. IMPORTANCE: Non-typeable Haemophilus influenzae (NTHi) is a major human pathogen for which there is no vaccine. Subunits for a rationally designed vaccine need to be conserved and present in almost all strains of an organism, be stably expressed, and be surface-located, so they will be “recognized” by the immune system. Our work sought to determine if a highly conserved NTHi protein, NTHI1101, was surface-located and required for pathobiology. Characterization showed that this protein was located in the outer membrane, but not present on the bacterial cell surface, and not required for key aspects of disease. We therefore conclude that NTHI1101 should not be further investigated as a vaccine candidate, so that ineffective antigens are not included in an NTHi vaccine.

  • Picomolar detection of carbohydrate-lectin interactions on piezoelectrically printed microcantilever array

    by Oren Cooper, Hoang-Phuong Phan, Tom Fitzpatrick, Toan Dinh, Han Huang, Nam-Trung Nguyen, Joe Tiralongo


  • Open Access

    Bacteriophage adaptation to a mammalian mucosa reveals a trans-domain evolutionary axis

    by Wai Hoe Chin, Ciaren Kett, Oren Cooper, Deike Müseler, Yaqi Zhang, Rebecca Bamert, Ruzeen Patwa, Laura C. Woods, Citsabehsan Devendran, Joe Tiralongo, et al.

    The majority of viruses within the human gut are obligate bacterial viruses known as bacteriophages (phages) 1 . Their bacteriotropism underscores the study of phage ecology in the gut, where they sustain top-down control 2–4 and co-evolve 5 with gut bacterial communities. Traditionally, these were investigated empirically via in vitro experimental evolution 6–8 and more recently, in vivo models were adopted to account for gut niche effects 4,9 . Here, we probed beyond conventional phage-bacteria co-evolution to investigate the potential evolutionary interactions between phages and the mammalian “host”. To capture the role of the mammalian host, we recapitulated a life-like mammalian gut mucosa using in vitro lab-on-a-chip devices (to wit, the gut-on-a-chip) and showed that the mucosal environment supports stable phage-bacteria co-existence. Next, we experimentally evolved phage populations within the gut-on-a-chip devices and discovered that phages adapt by de novo mutations and genetic recombination. We found that a single mutation in the phage capsid protein Hoc – known to facilitate phage adherence to mucus 10 – caused altered phage binding to fucosylated mucin glycans. We demonstrated that the altered glycan-binding phenotype provided the evolved mutant phage a competitive fitness advantage over their ancestral wildtype phage in the gut-on-a-chip mucosal environment. Collectively, our findings revealed that phages – in addition to their evolutionary relationship with bacteria – are also able to engage in evolution with the mammalian host.